GASTRIC-MUCOSAL PROTECTION BY YM638, A NOVEL LEUKOTRIENE D-4 RECEPTOR ANTAGONIST, IN RATS

被引:2
|
作者
MIYATA, K
KAMATO, T
NISHIDA, A
TAKIZAWA, K
TAKEDA, M
机构
[1] Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co. Ltd., Tsukuba, Ibaraki, 305
关键词
YM638 ([[5-[[3-(4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY)PROPYL]THIO]-1,3,4-THIADIAZOL-2-YL]THIO] ACETIC ACID); LEUKOTRIENE D-4 RECEPTOR ANTAGONIST; GASTRIC MUCOSAL PROTECTION; GASTRIC LESION;
D O I
10.1016/0014-2999(95)00035-J
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
YM638 ([[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio] acetic acid) is a novel leukotriene D-4 receptor antagonist. We investigated the involvement of the leukotriene D-4 receptor blocking activity of YM638 in the gastric mucosal protection of this drug in rats. YM638 significantly prevented gastric lesion formation induced by water-immersion restraint stress, indomethacin, absolute ethanol, 0.7 N HCl and the combination of 0.2 N HCl and hemorrhagic shock, with ED(50) values of 26.4, 4.1, 4.7, 35.4 and 8.0 mg/kg p.o., respectively. Cetraxate and sofalcone showed inhibitory effects on most of these gastric lesions, but the inhibitory effects of these compounds were much weaker than those of YM638. In contrast, YM638 had no effect on gastric acid secretion and gastric lesion formation in pylorus-ligated rats, or on duodenal lesion formation in cysteamine-administered rats. YM638 competitively antagonized leukotriene D-4-induced contraction of the isolated stomach, with a pA(2) value of 7.63 +/- 0.18. In anesthetized rats, intravenous YM638 inhibited leukotriene D-4-induced aggravation of gastric lesions caused by HCl, and leukotriene D-4 and HCl-induced reduction of the potential difference. In addition, oral YM638 significantly increased gastric mucosal blood flow and prevented ethanol-induced increase in gastric vascular permeability. Endogenous prostaglandins, sulfhydryls and nitric oxides were not involved in this inhibitory effect on absolute ethanol-induced gastric lesion, YM638 did not react with the stable free radical 1,1-diphenyl-2-picrylhydrazyl in vitro, indicating that YM638 does not have potential as free radical scavenger. These results suggest that the preventive effect of YM638 on gastric lesions is attributable not only to its leukotriene D-4 receptor blocking activity but also to the activation of gastric mucosal defensive mechanisms such as mucosal blood flow and vascular permeability.
引用
收藏
页码:165 / 175
页数:11
相关论文
共 47 条
  • [1] Hepatic microsomal metabolism of montelukast, a potent leukotriene D-4 receptor antagonist, in humans
    Chiba, M
    Xu, X
    Nishime, JA
    Balani, SK
    Lin, JH
    DRUG METABOLISM AND DISPOSITION, 1997, 25 (09) : 1022 - 1031
  • [2] Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D-4 (LTD4) challenge in normal volunteers
    OShaughnessy, TC
    Georgiou, P
    Howland, K
    Dennis, M
    Compton, CH
    Barnes, NC
    THORAX, 1997, 52 (06) : 519 - 522
  • [3] A convergent synthesis of Ro24-5913, a novel leukotriene D-4 antagonist
    Maehr, H
    Yang, R
    TETRAHEDRON LETTERS, 1996, 37 (31) : 5445 - 5448
  • [4] PHARMACOLOGY OF MONTELUKAST SODIUM (SINGULAIR(TM)), A POTENT AND SELECTIVE LEUKOTRIENE D-4 RECEPTOR ANTAGONIST
    JONES, TR
    LABELLE, M
    BELLEY, M
    CHAMPION, E
    CHARETTE, L
    EVANS, J
    FORDHUTCHINSON, AW
    GAUTHIER, JY
    LORD, A
    MASSON, P
    MCAULIFFE, M
    MCFARLANE, CS
    METTERS, KM
    PICKETT, C
    PIECHUTA, H
    ROCHETTE, C
    RODGER, IW
    SAWYER, N
    YOUNG, RN
    ZAMBONI, R
    ABRAHAM, WM
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1995, 73 (02) : 191 - 201
  • [5] THE DISCOVERY OF L-699,392, A NOVEL POTENT AND ORALLY-ACTIVE LEUKOTRIENE D-4 RECEPTOR ANTAGONIST
    LABELLE, M
    BELLEY, M
    CHAMPION, E
    GORDON, R
    HOOGSTEEN, K
    JONES, TR
    LEBLANC, Y
    LORD, A
    MCAULIFFE, M
    MCFARLANE, C
    MASSON, P
    METTERS, KM
    NICOLLGRIFFITH, D
    OUIMET, N
    PIECHUTA, H
    ROCHETTE, C
    SAWYER, N
    XIANG, YB
    YERGEY, J
    FORDHUTCHINSON, AW
    PICKETT, CB
    ZAMBONI, RJ
    YOUNG, RN
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1994, 4 (03) : 463 - 468
  • [6] Characterization of the self-association properties of a leukotriene D-4 receptor antagonist, MK-0476
    Thibert, R
    Mach, H
    Clas, SD
    Meisner, DR
    Vadas, EB
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 134 (1-2) : 59 - 70
  • [7] EFFECT OF THE LEUKOTRIENE D-4 (LTD(4))-RECEPTOR ANTAGONIST BAY X 7195 ON LTD(4)-INDUCED BRONCHOCONSTRICTION IN NORMAL SUBJECTS
    WENSING, G
    HEINIG, R
    KUHLMANN, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (02) : 203 - 203
  • [8] The effect of a novel leukotriene C-4/D-4, antagonist, BAY-x-7195, on experimental allergic reactions
    Tanaka, H
    Nagai, H
    Takeda, H
    Yamaguchi, S
    Matsuo, A
    Inagaki, N
    PROSTAGLANDINS, 1995, 50 (5-6): : 269 - 285
  • [9] MONTELUKAST, A LEUKOTRIENE D-4 RECEPTOR ANTAGONIST, MAY PREVENT RAT TESTS AGAINST ISCHEMIA-REPERFUSION INJURY
    Silay, M. S.
    Toklu, H.
    Ozagari, A.
    Tanriverdi, O.
    Sener, G.
    Miroglu, C.
    Kendirci, M.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (06) : 577 - 577
  • [10] INHIBITION BY A NOVEL PEPTIDE LEUKOTRIENE RECEPTOR ANTAGONIST ONO-1078 OF AIRWAY WALL THICKENING AND AIRWAY HYPERRESPONSIVENESS TO HISTAMINE-INDUCED BY LEUKOTRIENE C-4 OR LEUKOTRIENE D-4 IN GUINEA-PIGS
    KUROSAWA, M
    YODONAWA, S
    TSUKAGOSHI, H
    MIYACHI, Y
    CLINICAL AND EXPERIMENTAL ALLERGY, 1994, 24 (10): : 960 - 968